Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?

Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?

Abstract Background Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2021-12, Vol.73 (11), p.e3990-e3995
Hauptverfasser: Pettit, Natasha N, Pisano, Jennifer, Nguyen, Cynthia T, Lew, Alison K, Hazra, Aniruddha, Sherer, Renslow, Mullane, Kathleen M
Format: Artikel
Sprache:eng
Schlagworte:
Major
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa1851